Co-Diagnostics, Inc.

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. was founded in 2013 by a team of molecular biology researchers, including Dwight Egan, who served as CEO through the company's initial public offering in 2019. The firm is headquartered in Salt Lake City, Utah, and went public on the Nasdaq under the ticker CODX. Its wealth origin traces to public equity markets and early private investment from founders and angel investors. The company's core strategy centers on its proprietary Co-Primer technology, a DNA-based platform designed to improve accuracy in polymerase chain reaction (PCR) testing. Co-Diagnostics initially targeted tuberculosis and malaria diagnostics, but shifted focus after the COVID-19 pandemic. Its Logix Smart COVID-19 Test received FDA Emergency Use Authorization in April 2020, followed by a CE-mark for the European market. The firm has also pursued tests for Zika, dengue, and influenza. Geographic footprint includes the US and international markets via distributor agreements in Africa, Latin America, and Europe. By 2021, Co-Diagnostics had recognized over $100M in revenue from its COVID-19 test sales, according to public filings. The company maintains a manufacturing facility in Salt Lake City and has pursued partnerships for point-of-care device integration. In August 2021, the firm announced a joint venture with a South African diagnostics distributor to expand into Sub-Saharan Africa (per SEC filing, August 2021). No additional offices beyond headquarters are publicly listed. Co-Diagnostics operates as a publicly traded diagnostics company rather than a traditional family office or fund. Its key structural differentiator is its Co-Primer platform, which the firm claims reduces false positives in multiplex PCR testing compared to conventional methods. The company's governance follows public company norms, with a board of directors and CEO oversight — distinct from the private, investor-driven structures typical of family offices.